Li Bingxin, Feng Xiaoyun, Zhang Yihan, Huang Yunhong, Gu Mingyu, Sun Haiyan, Ren Wenqian, Zhen Qin, Shen Tingting, Pan Ling, Fan Tingting, Qin Qin, Liu Fang, Peng Yongde, Wang Yufan, Xu Huanbai
Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghais, China.
Virulence. 2025 Dec;16(1):2441397. doi: 10.1080/21505594.2024.2441397. Epub 2024 Dec 27.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly, leading to an Omicron outbreak in Shanghai in mid-December after adjustments to the Coronavirus Disease 2019 (COVID-19) control strategy. To investigate the impact of COVID-19 infection among hypothyroid patients, we gathered data on the hypothyroid outpatients with COVID-19 infection during this time at the Thyroid Disease Center (TDC) of Shanghai Central Hospital. Patients were divided into two groups based on whether their hypothyroidism was caused by Hashimoto's Thyroiditis (HT): the HT and the non-HT group. We assessed the differences between pre-infection and clinical follow-up at one month (day (D) 30) and three months (D90) after COVID-19 infection. In HT group, thyroid-stimulating hormone (TSH) levels decreased significantly compared to pre-infection levels ( = 0.013), while free triiodothyronine (FT3) levels increased at D90 compared to both D30 post-infection and pre-infection levels ( < 0.001 and = 0.005). Hemoglobin levels also increased after COVID-19 infection ( = 0.033). For non-HT patients, FT3 levels increased at D30 compared to pre-infection levels ( = 0.017). Moreover, inactivated SARS-CoV-2 vaccination can preserve thyroid function stability in patients with hypothyroidism.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)迅速传播,在2019年冠状病毒病(COVID-19)防控策略调整后,12月中旬在上海引发了奥密克戎疫情。为了调查COVID-19感染对甲状腺功能减退患者的影响,我们收集了上海交通大学医学院附属新华医院甲状腺疾病中心在此期间COVID-19感染的甲状腺功能减退门诊患者的数据。根据甲状腺功能减退是否由桥本甲状腺炎(HT)引起,将患者分为两组:HT组和非HT组。我们评估了COVID-19感染前与感染后1个月(第30天)和3个月(第90天)临床随访之间的差异。在HT组中,促甲状腺激素(TSH)水平与感染前水平相比显著降低(=0.013),而游离三碘甲状腺原氨酸(FT3)水平在感染后第90天与感染后第30天和感染前水平相比均有所升高(<0.001和=0.005)。COVID-19感染后血红蛋白水平也有所升高(=0.033)。对于非HT患者,感染后第30天的FT3水平与感染前水平相比有所升高(=0.017)。此外,灭活SARS-CoV-2疫苗接种可维持甲状腺功能减退患者的甲状腺功能稳定。